BiOnSil
Milan
About BiOnSil
BiOnSil is a spin-off of the University of Milan-Bicocca, developing diagnostic and theranostic kits for the diagnosis of drug resistance in colorectal cancer; further down the product pipeline are also pharmacological inhibitors that could reduce carcinoma pharmacoresistance. The product platform is based on the researches of the team, that led to the identification of specific genes involved in drug resistance of colorectal cancer
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $4.3M
- Last round: Series Unknown (Jan 2010)
Industries & Categories
Health Diagnostics, Therapeutics
Canonical: https://fsome.com/organization/bionsil-2828735 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.